Xenon Pharmaceuticals Inc. - Common Stock (XENE)

Q3 2025 13F Holders as of 30 Sep 2025

Type / Class
Equity / Common Stock
Shares outstanding
77,331,078
Total 13F shares
84,320,819
Share change
+873,785
Total reported value
$3,385,181,214
Put/Call ratio
131%
Price per share
$40.15
Number of holders
218
Value change
+$50,763,723
Number of buys
99
Number of sells
91

Institutional Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q3 2025

As of 30 Sep 2025, Xenon Pharmaceuticals Inc. - Common Stock (XENE) was held by 218 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 84,320,819 shares. The largest 10 holders included FMR LLC, Avoro Capital Advisors LLC, BlackRock, Inc., Driehaus Capital Management LLC, JANUS HENDERSON GROUP PLC, WELLINGTON MANAGEMENT GROUP LLP, BRAIDWELL LP, Capital International Investors, Commodore Capital LP, and Polar Capital Holdings Plc. This page lists 218 institutional shareholders reporting positions in this security for the Q3 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.